Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | GAPDH | P04406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10388698 | 1.00 | TYMP (0.47) | TYMPTP53ALDH1A1LMNAMAPT | |
| SCHEMBL21382713 | 0.91 | TYMP (0.45) | TYMPTP53ALDH1A1LMNAMAPT | |
| SCHEMBL20908820 | 0.91 | TYMP (0.45) | TYMPTP53ALDH1A1LMNAMAPT | |
| SCHEMBL11910711 | 0.90 | TYMP (0.46) | TYMPTP53ALDH1A1LMNAMAPT | |
| SCHEMBL14424392 | 0.89 | TYMP (0.50) | TYMPTP53ALDH1A1LMNAMAPT | |
| SCHEMBL24453499 | 0.89 | TYMP (0.48) | TYMPTP53LMNAADORA1MEN1 | |
| SCHEMBL22220143 | 0.88 | ADORA1 (0.50) | ADORA1MEN1KMT2APDE4DSLC29A1 | |
| SCHEMBL21859282 | 0.88 | ADORA1 (0.50) | ADORA1MEN1KMT2APDE4DSLC29A1 | |
| SCHEMBL6762689 | 0.88 | ADORA1 (0.50) | ADORA1MEN1KMT2APDE4DSLC29A1 | |
| SCHEMBL21859151 | 0.88 | ADORA1 (0.50) | ADORA1MEN1KMT2APDE4DSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | GILEAD PALO ALTO, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | CV THERAPEUTICS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7553823-B2 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070207978-A1 | C-Pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | TYMP 864/4885TP53 2068/4885ALDH1A1 1336/4885 |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | ADORA2A, ADORA3, ADORA2B | TYMP 491/4885TP53 4038/4885ALDH1A1 1258/4885 |
| US-20070207978-A1 | C-Pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | TYMP 1121/4885TP53 4377/4885ALDH1A1 1002/4885 |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | ADORA2A, ADORA3, ADORA1 | TYMP 609/4885TP53 4421/4885ALDH1A1 1130/4885 |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | ADORA2A, ADORA3, ADRB3 | TYMP 1030/4885TP53 4642/4885ALDH1A1 2120/4885 |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | ADORA2A, FABP3, ADORA3 | TYMP 567/4885TP53 4592/4885ALDH1A1 1118/4885 |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | ADORA2A, ADORA3, TBXA2R | TYMP 1121/4885TP53 4377/4885ALDH1A1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.